Tanaka S, Tatsuguchi A, Futagami S, Gudis K, Wada K, Seo T, Mitsui K, Yonezawa M, Nagata K, Fujimori S, Tsukui T, Kishida T, Sakamoto C
Third Department of Internal Medicine, Nippon Medical School, 1-1-5, Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan.
Gut. 2006 Jan;55(1):54-61. doi: 10.1136/gut.2004.059824. Epub 2005 Aug 5.
Cyclooxygenase 2 (COX-2) expression in subepithelial macrophages of colorectal adenoma has been suggested as the first in a series of steps leading to colorectal tumorigenesis. We tested the hypothesis that chemokines released from human colorectal adenoma epithelium might be involved in COX-2 expression in macrophages of the lamina propria.
Endoscopic samples of sporadic colorectal adenomas were tested by enzyme linked immunosorbent assay for chemokines involved in macrophage chemotaxis. Localisation of adenoma macrophage chemoattractant protein 1 (MCP-1) and COX-2 were determined by immunohistochemistry. The effects of MCP-1, in the presence or absence of celecoxib, on COX-2 expression, and prostaglandin (PG) E(2) and vascular endothelial growth factor (VEGF) release, were examined in human macrophages isolated from peripheral blood.
MCP-1 levels were markedly higher in adenoma with mild-moderate dysplasia (129.7 (19.9) pg/mg protein) and severe dysplasia (227.9 (35.4) pg/mg protein) than in normal colonic mucosa (55.8 (4.2) pg/mg protein). Other chemokine levels, macrophage inflammatory proteins (MIP)-1alpha and MIP-1beta, and the chemokine regulated on activation of normal T cell expressed and secreted (RANTES) did not vary significantly between adenoma and normal mucosa. MCP-1 levels in both adenoma and normal colonic mucosa increased significantly three hours after tissue cultivation in vitro. MCP-1 immunoreactivity was restricted to the adenoma epithelium, with no reactivity seen in adjacent normal epithelial cells. MCP-1 stimulated COX-2 expression and PGE(2) and VEGF release in human macrophages. Celecoxib, a selective COX-2 inhibitor, inhibited MCP-1-induced PGE(2) and VEGF release in macrophages. Addition of exogenous PGE(2) reversed this inhibitory effect on VEGF release, suggesting that MCP-1 in adenoma epithelial cells might be involved in COX-2 expression and subsequent macrophage activation.
MCP-1 in colorectal adenoma epithelial cells might be involved in macrophage migration and COX-2 expression, leading to the subsequent development of colonic adenoma.
有研究表明,结直肠腺瘤上皮下巨噬细胞中环氧化酶2(COX-2)的表达是结直肠癌发生一系列步骤中的第一步。我们检验了这样一个假设,即人类结直肠腺瘤上皮释放的趋化因子可能参与固有层巨噬细胞中COX-2的表达。
通过酶联免疫吸附测定法检测散发性结直肠腺瘤的内镜样本中参与巨噬细胞趋化的趋化因子。采用免疫组织化学法确定腺瘤巨噬细胞趋化蛋白1(MCP-1)和COX-2的定位。在存在或不存在塞来昔布的情况下,检测MCP-1对从外周血分离的人类巨噬细胞中COX-2表达以及前列腺素(PG)E2和血管内皮生长因子(VEGF)释放的影响。
轻度至中度发育异常腺瘤(129.7(19.9)pg/mg蛋白质)和重度发育异常腺瘤(227.9(35.4)pg/mg蛋白质)中的MCP-1水平显著高于正常结肠黏膜(55.8(4.2)pg/mg蛋白质)。其他趋化因子水平,即巨噬细胞炎性蛋白(MIP)-1α和MIP-1β,以及正常T细胞激活后表达和分泌的趋化因子(RANTES),在腺瘤和正常黏膜之间无显著差异。腺瘤和正常结肠黏膜中的MCP-1水平在体外组织培养3小时后均显著升高。MCP-1免疫反应性仅限于腺瘤上皮,相邻正常上皮细胞未见反应性。MCP-1刺激人类巨噬细胞中COX-2表达以及PGE2和VEGF释放。选择性COX-2抑制剂塞来昔布抑制MCP-1诱导的巨噬细胞中PGE2和VEGF释放。添加外源性PGE2可逆转这种对VEGF释放的抑制作用,提示腺瘤上皮细胞中的MCP-1可能参与COX-2表达及随后的巨噬细胞激活。
结直肠腺瘤上皮细胞中的MCP-1可能参与巨噬细胞迁移和COX-2表达,从而导致结肠腺瘤的后续发展。